Cargando…
硼替佐米为基础的化疗序贯自体造血干细胞移植治疗伴1q21扩增初治多发性骨髓瘤患者疗效分析
OBJECTIVE: To explore the prognostic factors in newly diagnosed multiple myeloma (NDMM) patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation (ASCT). METHODS: We retrospectively assayed 35 NDMM patients with 1q21 a...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342915/ https://www.ncbi.nlm.nih.gov/pubmed/30032568 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2018.06.012 |
Ejemplares similares
-
1q21扩增对硼替佐米治疗初治多发性骨髓瘤患者疗效和预后的影响
Publicado: (2018) -
含硼替佐米方案诱导序贯自体造血干细胞移植治疗多发性骨髓瘤——单中心200例长期随访结果
Publicado: (2019) -
硼替佐米家庭治疗的探索
Publicado: (2020) -
血细胞积分对以硼替佐米为基础一线治疗的多发性骨髓瘤患者的预后评估作用
Publicado: (2020) -
硼替佐米、糖皮质激素为基础的联合方案治疗6例复发/难治免疫性血栓性血小板减少性紫癜
Publicado: (2023)